Imeroprubart clinical trials
Also written IMVT-1402.
How each study uses imeroprubart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the imeroprubart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 6 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Immunovant Sciences GmbH (8)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test imeroprubart.
- May 2027A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseasePhase 2 · Immunovant Sciences GmbH
- Sep 2027A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid ArthritisPhase 2 · Immunovant Sciences GmbH
Studies
Open first, then newest update. How each study uses imeroprubart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseaseRecruitingPhase 2Immunovant Sciences GmbHNCT07018323Written as IMVT-1402
- Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)RecruitingPhase 2Immunovant Sciences GmbHNCT07032662Written as Imeroprubart
- A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)Enrolling by invitationPhase 2Immunovant Sciences GmbHNCT07286006Written as IMVT-1402
- A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseaseRecruitingPhase 2Immunovant Sciences GmbHNCT06727604Written as IMVT-1402
- Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisRecruitingPhase 3Immunovant Sciences GmbHNCT07039916Written as IMVT-1402
- Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease ActivityActive, not recruitingPhase 2Immunovant Sciences GmbHNCT06979531Written as IMVT-1402
- A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)Active, not recruitingPhase 2Immunovant Sciences GmbHNCT06980805Written as IMVT-1402
- A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid ArthritisActive, not recruitingPhase 2Immunovant Sciences GmbHNCT06754462Written as IMVT-1402
Codes
What other systems call imeroprubart · ClinicalTrials.gg INT017567
- UNII (FDA) PBD3BZ3HW6IMEROPRUBARTOne source FDA
- NCI Thesaurus C211794ImeroprubartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PBD3BZ3HW6 | IMEROPRUBART | One source FDA |
| NCI Thesaurus | C211794 | Imeroprubart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.